by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
by | Jun 19, 2024 | Uncategorized
Source: CureToday articles One expert explains why double autologous stem cell transplantation is a viable alternative to back-to-back transplant in high-risk multiple myeloma. Read More
by | Jun 19, 2024 | Uncategorized
EJHaem. 2024 Apr 30;5(3):485-493. doi: 10.1002/jha2.907. eCollection 2024 Jun. ABSTRACT Belantamab mafodotin is the first-in-class antibody-drug conjugates targeting B-cell maturation antigen to have demonstrated effectiveness in triple-class refractory multiple...
by | Jun 18, 2024 | Uncategorized
CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about a study in older patients with relapsed/refractory multiple myeloma.The study was presented at ASCO Annual Meeting and investigated an oral two-drug regimen for frail patients with...
by | Jun 17, 2024 | Uncategorized
CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.A previous study assessing belantamab mafodotin monotherapy for the treatment of relapsed refractory multiple myeloma did...
by | Jun 17, 2024 | Uncategorized
CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, discussed findings assessing the treatment of patients with multiple myeloma who are ineligible for transplant.Fung, chair and professor in the bone marrow transplant and cellular therapies department at...
